Prescribing information

 

   

Explore our range of useful resources, designed to support you with your decision making. You can download the files to refer to later.

 

Thumbnail image of Cosentyx® (secukinumab) formulary application pack for non-radiographic axial spondyloarthritis (nr-axSpA)

Cosentyx® (secukinumab) formulary application pack for non-radiographic axial spondyloarthritis (nr-axSpA)

Information intended to support you with your local formulary submission for the use of Cosentyx in adults with non-radiographic axial spondyloarthritis (nr-axSpA).

Registration is required to access this resource.

Download resource

Thumbnail image of Cosentyx® (secukinumab) summary document

Cosentyx summary document

Information intended to support you with your local formulary submission or development of treatment guidelines for the use of Cosentyx in adults with plaque psoriasis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis.

Registration is required to access this resource.

Download resource

 

Image of Nice summary card

NICE summary card

Document detailing summary guidance for Cosentyx use in non-radiographic axial spondyloarthritis (nr-axSpA) from NICE.

Registration is required to access this resource.

Download resource

Image of SMC summary

SMC guidance

Cosentyx is accepted for use within NHSScotland in adults for the treatment of nr-axSpA.

This link will take you to the SMC website, which is a non-Novartis website.

View full guidance

 

Image of Cosentyx logo

Dermatology

If you are also a UK healthcare professional you can click below to view more information on Cosentyx® (secukinumab) in dermatology.

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

Image of Cosentyx logo

Rheumatology

If you are also a UK healthcare professional you can click below to view more information on Cosentyx® (secukinumab) in rheumatology.

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

 

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.1

 

CRP, c-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; NSAIDs, non-steroidal anti-inflammatory drugs; SMC, Scottish Medicines Consortium.

Reference:

  1. Cosentyx (secukinumab) SmPC, 2020.
Rate this content: 
0
No votes yet
UK | August 2021 | 148083

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]